| Literature DB >> 35014955 |
Keon Pearson1, Summer Ngo2, Eson Ekpo1, Ashish Sarraju2, Grayson Baird3, Joshua Knowles2, Fatima Rodriguez2.
Abstract
BACKGROUND: Lipoprotein(a) (Lp(a)) is a highly proatherogenic lipid fraction that is a clinically significant risk modifier. Patients wanting to learn more about Lp(a) are likely to use online patient educational materials (OPEMs). However, the readability of OPEMs may exceed the health literacy of the public.Entities:
Keywords: health education; health literacy; lipoprotein(a); online patient education material; readability
Mesh:
Substances:
Year: 2022 PMID: 35014955 PMCID: PMC8790699 DOI: 10.2196/31284
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Material selection and exclusion for OPEMs related to lipoprotein(a). OPEM: online patient education material.
Figure 2Average grade level readability of online patient education material (OPEM) by category of publication. Each circle represents a readability score for one OPEM, with a total of five readability scores for each unique OPEM. 95% CIs are included for all categories except “Clinic” and “Other,” which only had one unique OPEM each. University and government sources were significantly more readable than research and nonprofit foundation, industry, and lay press sources.
Figure 3Readability rankings by search result. Each blue dot corresponds to the mean readability based on the average of five standard readability scores (automated readability index, SMOG index, Coleman-Liau index, Gunning fog score, Flesch-Kincaid score) with whiskers representing the range of readability scores. The red vertical line corresponds to the AMA sixth grade level readability target. Cleveland Clinic1: Elevated Lipoprotein(a): Is a Long-Sought Treatment Finally on the Way?; Cleveland Clinic2: Why Would My Doctor Order a Lipoprotein(a) Blood Test?; National Lipid Association1: lipoprotein(a) Screening for Individuals at High ASCVD Risk; National Lipid Association2: Elevated Lipoprotein (a) Patient-Centered Education From the National Lipid Association. AMA: American Medical Association.
Search concepts and excerpts of readable and nonreadable quotes from OPEM.
| Concept | Excerpt from less readable OPEMa | Excerpt from more readable OPEM |
| Lp(a)b contains both a lipid and a protein carrier | “Lipoprotein(a), or Lp(a), is a distinctive particle with two components: a lipoprotein core that resembles LDL, along with a shell that contains apolipoprotein(a), or apo(a).” [ | “Lipoproteins are substances made up of protein and fat” [ |
| Lp(a) is a proatherogenic lipoprotein fraction | “High levels of LP(a) have now been identified as an independent risk factor in cardiovascular disease, with a causal link to atherosclerosis (furring up of arteries), heart attacks, strokes, aortic valve disease and heart failure.” [ | “High levels of Lp(a) can create plaque in your blood vessels.” [ |
| High-risk populations should be screened for Lp(a) | “Measurement of lipoprotein(a) is now recommended in several patient subgroups… patients with premature atherosclerosis; patients with a strong family history of premature coronary heart disease (CHD); patients with elevated LDL-C and greater than or equal to two risk factors; patients who have had coronary angioplasty in whom lipoprotein(a) excess may increase the risk of restenosis; patients who have undergone coronary bypass graft surgery in whom Lp(a) excess may be associated with graft stenosis.” [ | “You may need this test if you have: Heart disease, despite normal results on other lipid tests, High cholesterol, despite maintaining a healthy diet A family history of heart disease, especially heart disease that has occurred at an early age and/or sudden deaths from heart disease.” [ |
| There is no widely implemented standard for measuring Lp(a) | “Although the reference material for the accurate measurement of Lp(a) … has been available for many years, many commercial laboratories have not changed their reagents and testing methods and continue to use old reagents and methods resulting in inaccurate results. Accordingly, results of Lp(a) measurements by different labs are not comparable and some of them are clearly inaccurate.” [ | “Note: Normal value ranges may vary slightly among different laboratories. Talk to your doctor about the meaning of your specific test results.” [ |
| There are no drugs demonstrated to improve outcomes in patients with elevated Lp(a) | “Results using statin medications have been mixed in most trials … In severe cases, such as familial hypercholesterolemia or treatment- resistant hypercholesterolemia, lipid apheresis may dramatically reduce Lp(a) … Other medications that are in various stages of development include thyromimetics, cholesterol-ester-transfer protein (CETP inhibitors), anti-sense oligonucleopeptides, and proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors.” [ | “Medications/treatments in current use that lower Lp(a) also lower cholesterol. There are apheresis and niacin. These both have substantial side effects. PCSK9 inhibitors lower Lp(a) while lowering LDL cholesterol. Statins have no effect on Lp(a).” [ |
aOPEM: online patient educational material.
bLp(a): lipoprotein(a).